Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Single-tablet HIV regimen (NRTI + NNRTI + NRTI)

Emtricitabine with rilpivirine and tenofovir alafenamide

Brand names: Odefsey

A once-daily single-tablet HIV-1 regimen combining the non-nucleoside reverse transcriptase inhibitor rilpivirine with the nucleos(t)ide analogues emtricitabine and tenofovir alafenamide, used as complete antiretroviral therapy in adults and adolescents.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Rilpivirine binds and inhibits reverse transcriptase at a non-catalytic site, while emtricitabine and tenofovir alafenamide are incorporated into viral DNA by reverse transcriptase, causing chain termination.

Prescribing in practice

  • Rilpivirine absorption is acid-dependent, so proton pump inhibitors are contraindicated and antacids or H2 antagonists must be carefully time-separated and the dose taken with food.
  • Rilpivirine has been associated with QT prolongation, so caution is needed with other QT-prolonging drugs.
  • It is generally reserved for patients with a lower baseline viral load because of reduced efficacy at high viraemia.

Monitoring

Monitor HIV viral load and CD4 count along with liver function and renal parameters during treatment.

Counselling the patient

  • Take once daily with a meal, not on an empty stomach, to ensure absorption.
  • Avoid heartburn medicines that reduce stomach acid unless advised on safe spacing.
  • Keep taking it every day to prevent the virus becoming resistant.

Evidence & guidelines

Rilpivirine-based fixed-dose combinations are established options reflected in BHIVA guidance for suitable patients.

Reference: BHIVA HIV guidelines; EACS guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways